You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 CMV proportions and rates by covariates

From: Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience

  Total n Number with CMV (%) CMV rate per 100,000 patient days (95% CI) p-value
Total 435 70 (16.1) 18.2 (14.7, 22.5)  
Sex
 Female 164 27 (16.5) 19.1 (13.6, 26.7) 0.893
 Male 272 43 (15.9) 17.6 (13.4, 23.3)  
Age 65 and over
  < 65 396 58 (14.7) 16.4 (13.0, 20.7) 0.019
  ≥ 65 39 12 (30.8) 46.1 (26.8, 79.4)  
Transplant Hospital
 SCGH 232 33 (14.2) 14.60 (10.58, 20.16) 0.296
 RPH 206 40 (19.4) 22.53 (16.93, 29.99)  
Index graft history
 First graft 384 64 (16.7) 18.8 (15.0, 23.5) 0.425
 Had previous graft(s) 51 6 (11.8) 14.1 (7.0, 28.2)  
Number of grafts during follow up
 Single graft 432 69 (16.0) 18.0 (14.5, 22.3) 0.410
 Two grafts 3 1 (33.3) 191.2 (26.9, 1357.4)  
Donor & recipient CMV status (n = 430)
 DR 49 0 (0) 0 <0.001
 DR+ 115 13 (11.3) 11.0 (6.5, 18.6)  
 D+R 68 25 (36.8) 56.8 (40.0, 80.8)  
 D+R+ 195 32 (16.4) 18.9 (13.8, 25.9)  
HLA mismatch (index graft) (n = 432)
  < 2 mismatches 58 5 (8.6) 8.3 (3.7, 18.5) 0.153
  ≥ 2 mismatches 371 65 (17.5) 20.2 (16.2, 25.2)  
Antibody treatment
 None or before or at transplant only 394 59 (30.3) 15.0 (8.5, 26.5)  
 Post-transplant 33 11 (33.3) 18.8 (15.0, 23.7) 0.687
Rejection (any)
 No 342 51 (14.9) 16.3 (12.6, 21.1) 0.205
 Yes 93 19 (20.4) 35.3 (16.6, 35.3)  
Rejection (severe)
 No 407 63 (15.5) 16.7 (13.3, 21.1) 0.002
 Yes 28 7 (25.0) 38.3 (21.7, 67.4)  
Aboriginal
 No 386 63 (16.3) 18.3 (14.6, 22.9) 0.838
 Yes 49 7 (14.3) 17.6 (9.2, 33.8)  
Donor aged >60
 No 317 40 (12.6) 12.9 (9.6, 17.2) 0.002
 Yes 118 30 (25.2) 36.4 (26.5, 50.0)  
Deceased donor
 No 192 25 (13.0) 11.4 (7.8, 16.8) 0.017
 Yes 244 45 (18.5) 24.8 (19.2, 32.1)